Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma
NCT03023046Phase 2Completed
- Sponsor
- University of Washington
- Start
- Feb 2017
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, prednisone, vincristine sulfate liposome injection, cyclophosphamide, pegylated liposomal doxorubicin in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by University of Washington. Started Feb 2017; status: completed.
02
Drugs
etoposideprednisonevincristine sulfate liposome injectioncyclophosphamidepegylated liposomal doxorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03023046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023046.